Clobazam: pharmacological and therapeutic profile.

Hanks, G W

doi:10.1111/j.1365-2125.1979.tb04685.x

Cited by 29 publications

(13 citation statements)

References 22 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clobazam is 85% bound to serum proteins and its Vd is 1 L/kg. Elimination involves hydroxylation at the 4 position of the unsubstituted aromatic ring, resulting in the formation of 4‐hydroxyclobazam and 4‐hydroxy‐desmethylclobazam, both of which are subsequently conjugated and excreted in urine (Hanks, 1979; Volz et al, 1979). The half‐life of clobazam is 10–30 h, whilst the half‐life of N‐desmethylclobazam is 36–46 h. The desmethyl metabolite makes an important contribution to the pharmacological action (Aucamp, 1982) by accumulating to higher concentrations in serum than the parent drug.…”

Section: Relevance Of Tdm For Individual Aedsmentioning

confidence: 99%

Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies

et al. 2008

View full text Add to dashboard Cite

SUMMARYAlthough no randomized studies have demonstrated a positive impact of therapeutic drug monitoring (TDM) on clinical outcome in epilepsy, evidence from nonrandomized studies and everyday clinical experience does indicate that measuring serum concentrations of old and new generation antiepileptic drugs (AEDs) can have a valuable role in guiding patient management provided that concentrations are measured with a clear indication and are interpreted critically, taking into account the whole clinical context. Situations in which AED measurements are most likely to be of benefit include (1) when a person has attained the desired clinical outcome, to establish an individual therapeutic concentration which can be used at subsequent times to assess potential causes for a change in drug response; (2) as an aid in the diagnosis of clinical toxicity; (3) to assess compliance, particularly in patients with uncontrolled seizures or breakthrough seizures; (4) to guide dosage adjustment in situations associated with increased pharmacokinetic variability (e.g., children, the elderly, patients with associated diseases, drug formulation changes); (5) when a potentially important pharmacokinetic change is anticipated (e.g., in pregnancy, or when an interacting drug is added or removed); (6) to guide dose adjustments for AEDs with dose-dependent pharmacokinetics, particularly phenytoin.

show abstract

Section: Relevance Of Tdm For Individual Aedsmentioning

confidence: 99%

Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies

et al. 2008

View full text Add to dashboard Cite

show abstract

“…There are no drug interactions with other ASDs. 1 In one study, phenytoin (PHT) intoxication was reported in 3 patients when CLB was added to PHT. 2 This may be due to interference with the CYP2C19 component of PHT metabolism.…”

Section: Clobazammentioning

confidence: 98%

“…1 Pharmacology CLB is completely absorbed following oral administration with peak plasma levels in 1-4 hours and elimination half-life 18 hours. It is 90% protein bound and it is metabolized by N-demethylation by CYP3A4 and to a lesser extent by CYP2C19 and CYP2B6.…”

Section: Clobazammentioning

confidence: 99%

An overview of third-generation antiseizure drugs

Spanaki

Barkley

2012

Neur Clin Pract

View full text Add to dashboard Cite

Four antiseizure drugs have been approved in the United States since 2008. Clobazam, a 1,5-benzodiazepine, was approved in October 2011 as an adjunctive therapy for Lennox-Gastaut syndrome (LGS) in patients 2 years and older. Lacosamide, an amino acid that selectively enhances the slow inactivation of voltage-gated sodium channels, was approved in October 2008 as an add-on therapy for partial onset seizures in patients 17 years and older. Rufinamide, a triazole derivative, was approved in November 2008 as an adjunctive therapy for LGS in patients 4 years and older. Vigabatrin, an irreversible inhibitor of GABA transaminase, was approved in August 2009 for the treatment of infantile spasms in children ages 1 month to 2 years and intractable complex partial seizures in adults.

show abstract

“…No se practicaron mediciones plasmaticas de niveles de clobazam: Segun la literatura disponible el clobazam no modiflca significativamente los niveles plasmaticos de otros anticonvulsivantes 16 , por lo cual cualquier modification en la frecuencia de las crisis debiera ser considerada respuesta a la accion especifica del clobazam. En ausencia de una clasificacion de las epilepsias adaptada al lactante y al nino nos basamos en la de Masland y clasificamos las epilepsias de la siguiente manera:…”

Section: Materials Y Metodounclassified

Clobazam en Epilepsias Refractarias del Niño

E¹,

Sch²,

A³

1984

Rev. chil. pediatr.

View full text Add to dashboard Cite

Clobazam in Children with Refractory EpilepsyTwenty three patients with refractory epilepsy (14 males and 9 females) and high seizure frecuency, all younger than 18 years old, were treated with Clobazam (Frizin®) added to conventional anticonvulsants. Doses of 0,5 -2 mg/kg/day, not exceeding 40 rng/day, were used. Complete seizure relief was achieved in 46% of the cases (11 patients) for an average follow up period of 5 months and 27 days. An important reduction in the frecuency of seizures was seen in 21% of the patients (5 cases). Recurrence of seizures after 2 to 3 months of good response to treatment ocurred in 5 patients (21 %). The best results were observed in secondary generalized epilepsies.El tratamiento de la epilepsia refractaria aun represents un desafio clinico a pesar de la introduction de nuevas drogas anticonvulsivantes. Partimos de la base que la monoterapia, con control de niveles plasmaticos es el tratamiento de election, sin embargo en algunos pacientes no se logra buena respuesta con una o mas drogas anticonvulsivantes, muchas de las cuales tienen efectos colaterales potencialmente serios.

show abstract

Clobazam: pharmacological and therapeutic profile.

Cited by 29 publications

References 22 publications

Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies

Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies

An overview of third-generation antiseizure drugs

Clobazam en Epilepsias Refractarias del Niño

Contact Info

Product

Resources

About